At the same time, BH3 mimetics, including drugs directed against the anti-apoptotic factors BCL2 and MCL1, represent an attractive class of inhibitors in SCLC but it remains unclear which molecular factors prime susceptibility to these targets10. This evidence concerns the gene MCL1 and small cell lung carcinoma.